Group 1 - Hong Kong Stock Exchange criticized Fuhong Hanlin for misusing IPO fundraising, highlighting governance and compliance issues [1] - Fuhong Hanlin's former CEO Liu Shigao was also reprimanded and required to undergo training [1] Group 2 - Xiansheng Pharmaceutical plans to raise approximately HKD 15.54 billion through a placement of 121 million shares at HKD 12.95 each, with about 90% allocated for R&D [2] - The funding will support clinical research for new drugs in China and the US, as well as expanding indications for approved innovative drugs [2] Group 3 - Huajian Medical announced the acquisition of a 20.31% stake in Guofu Quantum for approximately HKD 31.42 billion, making it the largest shareholder [3] - This acquisition is a strategic move to advance Huajian Medical's RWA (Real World Asset) tokenization initiative [3] Group 4 - Lighter Health Group submitted a prospectus for listing on the Hong Kong Stock Exchange, focusing on comprehensive health services and insurance solutions [4] - The company reported significant revenue growth from HKD 394 million in 2022 to HKD 945 million in 2024, but experienced a decline in gross margin from 82.6% to 38.3% [4]
港交所谴责复宏汉霖擅改上市募资用途；华检医疗收购国富量子20.3%股权丨港交所早参